4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
4 citations
,
September 2023 in “Journal of Dermatological Treatment” Red and near-infrared light-emitting fabric may help improve psoriasis, PMLE, and alopecia areata.
November 2025 in “Journal of Investigative Dermatology”
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
June 2026 in “Frontiers in Oncology” Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.
13 citations
,
January 2018 in “International Journal of Trichology” Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
18 citations
,
August 2012 in “Cutaneous and Ocular Toxicology” People with alopecia areata have higher insulin resistance.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
June 2026 in “EJC Paediatric Oncology” High-dose thiotepa and twice-daily treatments increase the risk of permanent hair loss in children receiving craniospinal irradiation.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
8 citations
,
January 2024 in “Journal of Materials Chemistry B” ADM hydrogels help heal radiation skin injuries.
4 citations
,
February 2025 in “BMC Genomics” Black wool in Qira sheep is linked to specific gene mutations, especially in the TYRP1 gene.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
RXR and RAR proteins in skin may help with cell growth, hair growth, and gland function.
3 citations
,
April 2024 in “International Journal of Women’s Dermatology” Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
July 2022 in “Media Dermato Venereologica Indonesiana” The combination of PRP and triamcinolone injections improved hair growth in a man with alopecia areata.
13 citations
,
January 1999 in “Postgraduate Medicine” New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
September 2017 in “Griffith Research Online (Griffith University, Queensland, Australia)” Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.
16 citations
,
July 2018 in “Dermatologic Surgery” iL-PRF treatment improves hair growth for androgenetic alopecia.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
May 2026 in “Journal of Asia Pacific Aesthetic Sciences” Low-dose intralesional corticosteroid treatment led to rapid hair regrowth in localized alopecia areata.